艾立布林脂质体制剂(E7389-LF)的1期研究:乳腺癌扩展队列结果
本研究为1期研究的乳腺癌扩展队列,评估E7389-LF 2.0 mg/m²每三周方案在人表皮生长因子受体2阴性转移性乳腺癌患者中的安全性和疗效。28例患者中,客观缓解率35.7%,激素受体阳性亚组42.9%,中位无进展生存期5.7个月,中位总生存期18.3个月。常见≥3级治疗相关不良事件包括中性粒细胞减少(67.9%)和发热性中性粒细胞减少(25.0%)。
要点
- E7389-LF 2.0 mg/m²每三周方案在HER2阴性转移性乳腺癌中观察到抗肿瘤活性,激素受体阳性亚组更为明显。
- 常见≥3级治疗相关不良事件为中性粒细胞减少(67.9%)、白细胞减少(42.9%)、血小板减少(32.1%)和发热性中性粒细胞减少(25.0%)。
- 作者建议(弱推荐)可考虑对中性粒细胞减少和发热性中性粒细胞减少高风险患者使用预防性聚乙二醇非格司亭。
核心结论
- E7389-LF可耐受,并观察到有利的抗肿瘤活性,尤其在激素受体阳性乳腺癌患者中。
研究设计与样本
- 1期研究的乳腺癌扩展队列,纳入人表皮生长因子受体2阴性转移性乳腺癌患者28例。
- 患者接受E7389-LF 2.0 mg/m²每三周给药,每六周由研究者按实体瘤疗效评价标准v1.1进行肿瘤评估。
主要发现
- 28例患者中,激素受体阳性乳腺癌占75.0%,三阴性乳腺癌占25.0%。
- 最常见的≥3级治疗相关治疗中出现的不良事件包括中性粒细胞减少(67.9%)、白细胞减少(42.9%)、血小板减少(32.1%)和发热性中性粒细胞减少(25.0%)。
- 接受预防性聚乙二醇非格司亭的患者中,中性粒细胞减少和发热性中性粒细胞减少的发生率较低。
- 全部患者的客观缓解率为35.7%(95%CI:18.6-55.9),激素受体阳性乳腺癌患者为42.9%(95%CI:21.8-66.0)。
- 中位无进展生存期为5.7个月(95%CI:3.9-8.3),中位总生存期为18.3个月(95%CI:13.2-不可估计)。
临床怎么用
- 作者建议(弱推荐)可考虑对中性粒细胞减少和发热性中性粒细胞减少高风险患者使用预防性聚乙二醇非格司亭。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A liposomal formulation of eribulin, E7389-LF, may provide improved pharmacokinetics and allow increased access to tumour tissues. This expansion of a phase 1 study assessed the safety and efficacy of E7389-LF in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. METHODS: Patients received E7389-LF 2.0 mg/m2 every three weeks. Tumour assessments were conducted every six weeks by the investigator by Response Evaluation Criteria in Solid Tumours v1.1. All adverse events were monitored and recorded. Serum biomarker assessments were conducted. RESULTS: Of 28 patients included, 75.0% had hormone receptor-positive breast cancer (HR+ BC) and 25.0% had triple-negative breast cancer (TNBC). The most common grade ≥3 treatment-related treatment-emergent adverse events included neutropenia (67.9%), leukopenia (42.9%), thrombocytopenia (32.1%), and febrile neutropenia (25.0%). Rates of neutropenia and febrile neutropenia were lower among patients who received prophylactic pegfilgrastim. Objective response rate was 35.7% (95% confidence interval [CI]: 18.6-55.9) for all patients and 42.9% (95% CI: 21.8-66.0) for patients with HR+ BC. Median progression-free survival was 5.7 months (95% CI: 3.9-8.3). The median overall survival was 18.3 months (95% CI: 13.2-not estimable). Among the 54 biomarkers assessed, 27, including 5 of 7 vascular markers, were significantly altered by E7389-LF treatment from baseline to any time point. CONCLUSION: E7389-LF was tolerable and favourable antitumour activity was observed, particularly in patients with HR+ BC. Prophylactic pegfilgrastim can be considered in patients at high risk for neutropenia and febrile neutropenia. GOV NUMBER: NCT03207672.
引用
- Masuda N, Ono M, Mukohara T, et al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort. Eur J Cancer. 2022. PMID: 35500404. doi:10.1016/j.ejca.2022.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。